Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, filed this Form 6-K on May 19, 2020. The filing serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed within this document.
Material Changes
The filing text does not provide details regarding material changes versus prior periods. The document acts solely as a conduit for the attached press release, the content of which is not included in the source text.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the filing text. These elements are presumed to be contained within the referenced press release (Exhibit 99.1), which is not provided in the input.
Key Facts for Investor Verification
- Verify the content of the press release dated May 19, 2020, referenced as Exhibit 99.1, as the filing itself contains no substantive operational or financial details.
- Confirm the company's status as a Form 20-F filer and its principal executive office location in Geneva, Switzerland.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on May 19, 2020.